Troponin Trajectories After Myocardial Infarction

Why Troponin Timing Matters After Myocardial Infarction

After a myocardial infarction (MI), troponin can rise sharply as injured heart muscle releases the protein into the circulation, then fall as the acute episode resolves. A measurement taken during that rise or fall answers a different question from a measurement taken weeks later. Treating all post-MI values as observations of one stable trajectory can therefore obscure what a longitudinal-survival analysis is estimating.

A joint model can relate repeated troponin measurements to time until death or a subsequent cardiovascular event while accounting for measurement error and the dependence between the two processes. The clinical time axis is central: a model starting at MI onset includes the acute phase and early events, whereas one starting at discharge describes risk among people who survived to discharge. Neither target is automatically preferable; the choice must be explicit.

For a first-event analysis, the endpoint should be stated precisely, for example, “death or first recurrent cardiovascular event after MI.” If the scientific question concerns multiple recurrent events, a first-event survival model does not by itself answer it. The time origin must also be recorded: MI onset, hospital admission, or discharge are not interchangeable origins.

Representing Acute and Later Measurements

Troponin assays differ, and concentrations are commonly right-skewed. A typical analysis models the natural logarithm of concentration, \(Z_{ij}=\log(Y_{ij})\), when values are positive and the log scale is scientifically and statistically suitable. The unit should be consistent, such as ng/L, because changing units shifts log values. Measurements below an assay’s detection limit should be handled using an appropriate censored-measurement likelihood, rather than automatically replaced by zero or by an arbitrary constant.

A useful model distinguishes the acute period from later follow-up. Let \(\tau\) be a prespecified transition time, chosen using clinical knowledge and the study schedule. A flexible mixed model can represent the mean trajectory with separate functions for the two phases and person-specific random effects:

Here \(f_A\) describes the acute rise-and-fall pattern, and \(f_L\) describes later follow-up; these functions may use prespecified splines or other suitable terms. The random effects allow individuals to differ in their acute level or later level and slope. The residuals \(\varepsilon_{ij}\) represent measurement-level variation. A fitted model may impose continuity at \(\tau\), or allow a change in level if that is justified by the measurement process and clinical question. The choice should be made deliberately, not as an accidental consequence of coding.

For example, a study beginning at MI onset might use a survival submodel with phase-specific current-value associations:

In this expression, \(h_0(t)\) is the baseline hazard, \(\mathbf{w}_i\) contains measured covariates, and \(\mathbf{b}_i\) denotes the person’s random effects. The coefficients \(\alpha_A\) and \(\alpha_L\) allow the association between latent log troponin and event hazard to differ in the acute and later phases. This is an associational model, not a claim that changing troponin would change a person’s outcome.

The model requires more than a good curve fit. The phase structure and time origin must match the clinical question; the longitudinal distribution and functional forms must be adequate; and event and censoring times must be recorded appropriately. A common assumption is that censoring is independent of the event time conditional on modeled covariates and random effects. The observation process also matters: if worsening patients are measured more often, the visit schedule may be informative and should be assessed rather than assumed ignorable.

How the Association Is Interpreted

The current-value link gives a direct interpretation of a phase-specific coefficient. Holding time, covariates, and the other model components fixed, an increase of \(d\) units in latent log troponin changes the modeled hazard by a factor of \(\exp(\alpha d)\). Since the logarithm is used, a doubling in concentration corresponds to an increase of \(\log(2)\) in log concentration.

The cancellation shows why the hazard ratio is conditional on the same time and other modeled quantities. It does not compare two different calendar times, at which the baseline hazard may differ. The latent trajectory is used because a single observed troponin value includes measurement error and may not represent the underlying level.

Model Checks, Alternatives, and Limitations

The central diagnostic question is whether the model captures the distinct shapes and timing of acute and later troponin. Plot measurements by time since MI, inspect fitted trajectories against observed values, and examine residual patterns by phase. Check sensitivity to the transition time \(\tau\), the selected spline complexity, and the treatment of values below detection limits. For the event component, assess whether the chosen baseline hazard and covariate effects are adequate and whether the phase-specific association estimates are stable. Investigate whether measurement frequency changes with clinical status; a joint model does not automatically correct an informative visit schedule.

Several alternatives answer different questions. A Cox model using one troponin value at baseline is simpler, but discards subsequent trajectory information and may be sensitive to when that value was taken. A time-dependent Cox model using the most recent observed value can describe updated measurements, but treats them as error-free and may be affected by irregular measurement timing. A landmark analysis predicts outcomes after a chosen time using information available by that time; it is useful for a clearly defined survivor population but excludes events before the landmark. A joint model is useful when the latent trajectory and event process are linked, but it requires stronger modeling assumptions and careful estimation.

The choice of time origin can change the population and estimand. Starting at discharge conditions on surviving to discharge, so it cannot describe the risk from the moment of infarction. Starting at MI onset includes early events, but demands an appropriate model for acute measurements and early risk. Also, measured troponin can reflect infarct size, renal function, treatment, and other prognostic factors. Adjustment for measured covariates can reduce some confounding, but neither adjustment nor joint modeling alone supports a causal interpretation.

• Pitfall: treating acute and late values as interchangeable. The incorrect reasoning is that every value is just another noisy observation of one steady biomarker level. The correction is to align measurements to MI onset, represent acute kinetics separately, and define what the later trajectory is intended to measure.
• Pitfall: starting follow-up at discharge but interpreting results from MI onset. The discharge cohort excludes earlier deaths and events. State the survivor population and the discharge time origin, or use an onset-based design that includes early outcomes.
• Pitfall: reading a hazard ratio as a risk ratio or causal effect. A hazard ratio compares instantaneous event rates conditional on the model; it is not a probability ratio over a fixed period and does not by itself establish causation.